PLA2G10 Gene Variants, sPLA2 Activity, and Coronary Heart Disease Risk

Circulation: Cardiovascular Genetics

Volumn 8, Issue 2, 2015, Pages 356-362

  Guardiola, Montse ^a,c   Exeter, Holly J ^a   Perret, Claire ^d   Folkersen, Lasse ^e,f   Van'T Hooft, Ferdinand ^f,g   Eriksson, Per ^f,h   Franco Cereceda, Anders ⁱ   Paulsson Berne, Gabrielle ^f   Palmen, Jutta ^a   Li, Kawah ^a   Cooper, Jackie A ^a   Khaw, Kay Tee ^j   Mallat, Ziad ^d   Ninio, Ewa ^d   Karabina, Sonia Athina ^d,k   Humphries, Steve E ^a   Boekholdt, S Matthijs ^l   Holmes, Michael V ^b,l   Talmud, Philippa J ^a  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^d SORBONNE UNIVERSITÉ   (France)

^e NOVO NORDISK A S   (Denmark)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g Department of Medicine Solna   (Sweden)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k ACADEMIC MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

genetic polymorphism; PLA2G10

Indexed keywords

SECRETORY PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 GROUP X; PLA2G10 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CORONARY RISK; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PLA2G10 GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; ENZYMOLOGY; FOLLOW UP; GENETICS; META ANALYSIS (TOPIC); MIDDLE AGED; MULTICENTER STUDY; QUANTITATIVE TRAIT; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; GROUP X PHOSPHOLIPASES A2; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; QUANTITATIVE TRAIT, HERITABLE; RISK FACTORS;

EID: 84937135089     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.114.000633     Document Type: Article

References (38)

1. Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation. 1999;100:1280-1284.
2. Kugiyama K, Ota Y, Sugiyama S, Kawano H, Doi H, Soejima H, et al. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol. 2000;86:718-722.
3. Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol. 2005;25:839-846. doi: 10.1161/01.ATV.0000157933.19424.b7.
4. Xin H, Chen ZY, Lv XB, Liu S, Lian ZX, Cai SL. Serum secretory phospholipase A2-IIa (sPLA2-IIA) levels in patients surviving acute myocardial infarction. Eur Rev Med Pharmacol Sci. 2013;17:999-1004.
5. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol. 2007;27:1177-1183. doi: 10.1161/ATVBAHA.107.139352.
6. Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol. 2005;46:1249-1257. doi: 10.1016/j.jacc.2005.06.056.
7. Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J. 2009;30:2742-2748. doi: 10.1093/eurheartj/ehp302.
8. Rouault M, Le Calvez C, Boilard E, Surrel F, Singer A, Ghomashchi F, et al. Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor. Biochemistry. 2007;46:1647-1662. doi: 10.1021/bi062119b.
9. Yamamoto K, Isogai Y, Sato H, Taketomi Y, Murakami M. Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics. Anal Bioanal Chem. 2011;400:1829-1842. doi: 10.1007/s00216-011-4864-z.
10. Ivandic B, Castellani LW, Wang XP, Qiao JH, Mehrabian M, Navab M, et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol. 1999;19:1284-1290.
11. Leitinger N, Watson AD, Hama SY, Ivandic B, Qiao JH, Huber J, et al. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol. 1999;19:1291-1298.
12. Boyanovsky B, Zack M, Forrest K, Webb NR. The capacity of group V sPLA2 to increase atherogenicity of ApoE?/? and LDLR?/? mouse LDL in vitro predicts its atherogenic role in vivo. Arterioscler Thromb Vasc Biol. 2009;29:532-538. doi: 10.1161/ATVBAHA.108.183038.
13. Singer AG, Ghomashchi F, Le Calvez C, Bollinger J, Bezzine S, Rouault M, et al. Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem. 2002;277:48535-48549. doi: 10.1074/jbc.M205855200.
14. Hanasaki K, Yamada K, Yamamoto S, Ishimoto Y, Saiga A, Ono T, et al. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem. 2002;277:29116-29124. doi: 10.1074/jbc.M202867200.
15. Curfs DM, Ghesquiere SA, Vergouwe MN, van der Made I, Gijbels MJ, Greaves DR, et al. Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology. J Biol Chem. 2008;283:21640-21648. doi: 10.1074/jbc.M710584200.
16. Gora S, Perret C, Jemel I, Nicaud V, Lambeau G, Cambien F, et al. Molecular and functional characterization of polymorphisms in the secreted phospholipase A2 group X gene: relevance to coronary artery disease. J Mol Med (Berl). 2009;87:723-733. doi: 10.1007/s00109-009-0483-y.
17. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, et al. EPICNorfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999;80 Suppl 1:95-103.
18. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation. 2000;102:2816-2822.
19. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis. 2006;187:415-422. doi:10.1016/j.atherosclerosis.2005.09.023.
20. Stram DO. Software for tag single nucleotide polymorphism selection. Hum Genomics. 2005;2:144-151.
21. Day IN, Humphries SE, Richards S, Norton D, Reid M. High-throughput genotyping using horizontal polyacrylamide gels with wells arranged for microplate array diagonal gel electrophoresis (MADGE). Biotechniques. 1995;19:830-835.
22. Folkersen L, van't Hooft F, Chernogubova E, Agardh HE, Hansson GK, Hedin U, et al; BiKE and ASAP study groups. Association of genetic risk variants with expression of proximal genes identifies novel susceptibility genes for cardiovascular disease. Circ Cardiovasc Genet. 2010;3:365-373. doi: 10.1161/CIRCGENETICS.110.948935.
23. Razuvaev A, Ekstrand J, Folkersen L, Agardh H, Markus D, Swedenborg J, et al. Correlations between clinical variables and gene-expression profiles in carotid plaque instability. Eur J Vasc Endovasc Surg. 2011;42:722-730. doi: 10.1016/j.ejvs.2011.05.023.
24. Holmes MV, Simon T, Exeter HJ, Folkersen L, Asselbergs FW, Guardiola M, et al. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol. 2013;62:1966-1976. doi: 10.1016/j.jacc.2013.06.044.
25. Holmes MV, Exeter HJ, Folkersen L, Nelson CP, Guardiola M, Cooper JA, et al.; CARDIoGRAM Consortium. Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels. Circ Cardiovasc Genet. 2014;7:144-150. doi: 10.1161/CIRCGENETICS.113.000271.
26. Wootton PT, Arora NL, Drenos F, Thompson SR, Cooper JA, Stephens JW, et al. Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study. Hum Mol Genet. 2007;16:1437-1444. doi: 10.1093/hmg/ddm094.
27. Wootton PT, Drenos F, Cooper JA, Thompson SR, Stephens JW, Hurt-Camejo E, et al. Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. Hum Mol Genet. 2006;15:355-361. doi: 10.1093/hmg/ddi453.
28. Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation. 2010;122:2183-2200. doi: 10.1161/CIRCULATIONAHA.110.936393.
29. Zhou L, Nilsson A. Sources of eicosanoid precursor fatty acid pools in tissues. J Lipid Res. 2001;42:1521-1542.
30. Exeter HJ, Folkersen L, Palmen J, Franco-Cereceda A, Cooper JA, Kalea AZ, et al. Functional analysis of two PLA2G2A variants associated with secretory phospholipase A2-IIA levels. PLoS One. 2012;7:e41139. doi: 10.1371/journal.pone.0041139.
31. Masuda S, Murakami M, Ishikawa Y, Ishii T, Kudo I. Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues. Biochim Biophys Acta. 2005;1736:200-210. doi: 10.1016/j. bbalip.2005.08.014.
32. Hallstrand TS, Chi EY, Singer AG, Gelb MH, Henderson WR Jr. Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness. Am J Respir Crit Care Med. 2007;176:1072-1078. doi: 10.1164/rccm.200707-1088OC.
33. Henderson WR Jr, Chi EY, Bollinger JG, Tien YT, Ye X, Castelli L, et al. Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J Exp Med. 2007;204:865-877. doi: 10.1084/jem.20070029.
34. Karabina SA, Brochériou I, Le Naour G, Agrapart M, Durand H, Gelb M, et al. Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function. FASEB J. 2006;20:2547-2549. doi: 10.1096/fj.06-6018fje.
35. Ait-Oufella H, Herbin O, Lahoute C, Coatrieux C, Loyer X, Joffre J, et al. Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol. 2013;33:466-473. doi: 10.1161/ATVBAHA.112.300309.
36. Fraser H, Hislop C, Christie RM, Rick HL, Reidy CA, Chouinard ML, et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/-mice. J Cardiovasc Pharmacol. 2009;53:60-65. doi: 10.1097/FJC.0b013e318195bfbc.
37. Nicholls SJ, Cavender MA, Kastelein JJ, Schwartz G, Waters DD, Rosenson RS, et al. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther. 2012;26:71-75. doi: 10.1007/s10557-011-6358-9.
38. Jemel I, Ii H, Oslund RC, Payré C, Dabert-Gay AS, Douguet D, et al. Group X secreted phospholipase A2 proenzyme is matured by a furin-like proprotein convertase and releases arachidonic acid inside of human HEK293 cells. J Biol Chem. 2011;286:36509-36521. doi: 10.1074/jbc.M111.268540.